EPISODE · Jul 10, 2026 · 13 MIN
MPR Weekly Dose Podcast #279 — Trutakna Approved; Xtoro and Amerithroid Now Available; Casgevy Approval Expanded; Lupus Tx Granted Breakthrough Designation
from MPR Weekly Dose
A new treatment is approved to reduce proteinuria in adults with primary immunoglobulin A nephropahty; a swimmer's ear treatment and the thyroid hormone replacement therapy Amerithroid are now available; Casgevy approval expanded include pediatrics; and a lupus treatment is granted breakthrough status.
Embed this episode
Ready to play
MPR Weekly Dose Podcast #279 — Trutakna Approved; Xtoro and Amerithroid Now Available; Casgevy Approval Expanded; Lupus Tx Granted Breakthrough Designation
0:00
13:35
1×
No transcript for this episode yet
Similar Episodes
No similar episodes found.
Similar Podcasts
No similar podcasts found.
Frequently Asked Questions
How long is this episode of MPR Weekly Dose?
This episode is 13 minutes long.
When was this MPR Weekly Dose episode published?
This episode was published on July 10, 2026.
Can I download this MPR Weekly Dose episode?
Yes. Use the download control on the episode player to save the publisher-provided media file.
URL copied to clipboard!